Nevertheless, current practice guidelines for HELLP emphasize stabilization and delivery, and C5 inhibition is not recommended yet for management and should be reserved for confirmed complement-mediated TMA/aHUS after excluding TTP and other causes (130). This evidence concerns the gene C5 and thrombotic thrombocytopenic purpura.